메뉴 건너뛰기




Volumn 9, Issue , 2015, Pages 6177-6183

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: Clinical results and biological observations in taxane-pretreated patients

Author keywords

Anthracyclines; Metastatic breast cancer; Nab paclitaxel

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAXANE DERIVATIVE; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; NANOPARTICLE; TAXOID;

EID: 84948168843     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S89575     Document Type: Article
Times cited : (20)

References (16)
  • 1
    • 84866597106 scopus 로고    scopus 로고
    • Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up
    • Cardoso F, Harbeck N, Fallowfield S, Kyriakides S, Senkus E; ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2012;23(suppl 7):vii11-vii19.
    • (2012) Ann Oncol. , vol.23 , pp. vii11-vii19
    • Cardoso, F.1    Harbeck, N.2    Fallowfield, S.3    Kyriakides, S.4    Senkus, E.5
  • 2
    • 46949103546 scopus 로고    scopus 로고
    • Metastatic breast cancer: The treatment challenge
    • Jones SE. Metastatic breast cancer: the treatment challenge. Clin Breast Cancer. 2008;8:224-233.
    • (2008) Clin Breast Cancer. , vol.8 , pp. 224-233
    • Jones, S.E.1
  • 3
    • 84868598489 scopus 로고    scopus 로고
    • Taxanes for the treatment of metastatic breast cancer
    • Gradishar WJ. Taxanes for the treatment of metastatic breast cancer. Breast Cancer. 2012;6:159-171.
    • (2012) Breast Cancer. , vol.6 , pp. 159-171
    • Gradishar, W.J.1
  • 5
    • 32944482677 scopus 로고    scopus 로고
    • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
    • Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794-7803.
    • (2005) J Clin Oncol. , vol.23 , pp. 7794-7803
    • Gradishar, W.J.1    Tjulandin, S.2    Davidson, N.3
  • 6
    • 2942655407 scopus 로고    scopus 로고
    • Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342
    • Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342. J Clin Oncol. 2004;22:2061-2068.
    • (2004) J Clin Oncol. , vol.22 , pp. 2061-2068
    • Winer, E.P.1    Berry, D.A.2    Woolf, S.3
  • 7
    • 84880182345 scopus 로고    scopus 로고
    • nab-Paclitaxel mechanisms of action and delivery
    • Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013;170:365-372.
    • (2013) J Control Release. , vol.170 , pp. 365-372
    • Yardley, D.A.1
  • 8
    • 68949114599 scopus 로고    scopus 로고
    • Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first line therapy for metastatic breast cancer
    • Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first line therapy for metastatic breast cancer. J Clin Oncol. 2009;27:3611-3619.
    • (2009) J Clin Oncol. , vol.27 , pp. 3611-3619
    • Gradishar, W.J.1    Krasnojon, D.2    Cheporov, S.3
  • 9
    • 84867058051 scopus 로고    scopus 로고
    • Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: Final analysis of overall survival
    • Gradishar WJ, Krasnojon D, Cheporov S, et al. Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012;12:313-321.
    • (2012) Clin Breast Cancer. , vol.12 , pp. 313-321
    • Gradishar, W.J.1    Krasnojon, D.2    Cheporov, S.3
  • 10
    • 38049079353 scopus 로고    scopus 로고
    • Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    • Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer. 2007;7:850-856.
    • (2007) Clin Breast Cancer. , vol.7 , pp. 850-856
    • Blum, J.L.1    Savin, M.A.2    Edelman, G.3
  • 11
    • 24944505659 scopus 로고    scopus 로고
    • Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
    • Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23:6019-6026.
    • (2005) J Clin Oncol. , vol.23 , pp. 6019-6026
    • Ibrahim, N.K.1    Samuels, B.2    Page, R.3
  • 12
    • 77956184020 scopus 로고    scopus 로고
    • Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    • Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010;123(2):427-435.
    • (2010) Breast Cancer Res Treat. , vol.123 , Issue.2 , pp. 427-435
    • Lobo, C.1    Lopes, G.2    Baez, O.3
  • 13
    • 84889100961 scopus 로고    scopus 로고
    • Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer
    • Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer. 2013;13(6):416-420.
    • (2013) Clin Breast Cancer. , vol.13 , Issue.6 , pp. 416-420
    • Hamilton, E.1    Kimmick, G.2    Hopkins, J.3
  • 14
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment on solid tumors
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment on solid tumors. J Natl Cancer Inst. 2000;92(3):205-216.
    • (2000) J Natl Cancer Inst. , vol.92 , Issue.3 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 15
    • 84929163847 scopus 로고    scopus 로고
    • Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: Prospective evaluation of activity, safety, and quality of life
    • Palumbo R, Sottotetti F, Trifirò G, et al. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther. 2015;9:1-11.
    • (2015) Drug Des Devel Ther. , vol.9 , pp. 1-11
    • Palumbo, R.1    Sottotetti, F.2    Trifirò, G.3
  • 16
    • 84876173108 scopus 로고    scopus 로고
    • An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: The COSTANza study
    • Lazzaro C, Bordonaro R, Cognetti F, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res. 2013;5:125-135.
    • (2013) Clinicoecon Outcomes Res. , vol.5 , pp. 125-135
    • Lazzaro, C.1    Bordonaro, R.2    Cognetti, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.